{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T02:14:04Z","timestamp":1794449644128,"version":"4.9.1"},"reference-count":116,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iScience"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.isci.2026.115213","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T16:28:11Z","timestamp":1772641691000},"page":"115213","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["CAR T-cells in hematologic malignancies: Advances, challenges, and future directions"],"prefix":"10.1016","volume":"29","author":[{"given":"Karol J.","family":"Hern\u00e1ndez-Idarraga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea J.","family":"Arias-Rozo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha L.","family":"Arango-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia L.","family":"Sossa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia M.","family":"Becerra-Bayona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.isci.2026.115213_bib1","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1186\/s12967-023-04292-3","article-title":"Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments","volume":"21","author":"Dagar","year":"2023","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.isci.2026.115213_bib2","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/bjh.17527","article-title":"Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma","volume":"194","author":"Oluwole","year":"2021","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.isci.2026.115213_bib3","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.115213_bib4","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.115213_bib5","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1182\/blood.2023021306","article-title":"CAR T cells and time-limited ibrutinib as treatment for relapsed\/refractory mantle cell lymphoma: the phase 2 TARMAC study","volume":"143","author":"Minson","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.isci.2026.115213_bib6","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1002\/jha2.970","article-title":"Real-world outcomes of patients with relapsed\/refractory large B-cell lymphoma receiving second-line therapy in England","volume":"5","author":"Fox","year":"2024","journal-title":"EJHaem"},{"key":"10.1016\/j.isci.2026.115213_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmorw.2025.100195","article-title":"Outcomes in relapsed\/refractory diffuse large B-cell lymphoma in an Asian tertiary cancer center: real-world interventions as benchmark for novel therapy","volume":"10","author":"Lim","year":"2025","journal-title":"ESMO Real World Data and Digital Oncology"},{"key":"10.1016\/j.isci.2026.115213_bib8","doi-asserted-by":"crossref","DOI":"10.4084\/MJHID.2024.045","article-title":"CAR-T Cells in Chronic Lymphocytic Leukemia","volume":"16","author":"Testa","year":"2024","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"10.1016\/j.isci.2026.115213_bib9","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1016\/j.clml.2024.11.014","article-title":"Real-World Effectiveness of Chemoimmunotherapy and Novel Therapies for Patients With Relapsed\/Refractory Aggressive Large B-Cell Lymphoma","volume":"25","author":"Nastoupil","year":"2025","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.isci.2026.115213_bib10","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s41408-025-01412-8","article-title":"Real-world treatment patterns and clinical outcomes among patients with diffuse large B-cell lymphoma in a US healthcare claims database","volume":"16","author":"Shadman","year":"2025","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.isci.2026.115213_bib11","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s40364-024-00589-7","article-title":"The CDK9 inhibitor enitociclib overcomes resistance to BTK inhibition and CAR-T therapy in mantle cell lymphoma","volume":"12","author":"Jiang","year":"2024","journal-title":"Biomark. Res."},{"key":"10.1016\/j.isci.2026.115213_bib12","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1038\/s41591-024-02986-9","article-title":"Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study","volume":"30","author":"Morschhauser","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2026.115213_bib13","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1002\/ajh.70027","article-title":"CD19 Directed CAR T Therapy for Transformed Follicular Lymphoma: A CIBMTR Analysis","volume":"100","author":"Thiruvengadam","year":"2025","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.isci.2026.115213_bib14","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1158\/2159-8290.CD-21-0407","article-title":"A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-PD-1 Agent Pembrolizumab","volume":"11","author":"Adusumilli","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.isci.2026.115213_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15133476","article-title":"Fine-Tuning through Generations: Advances in Structure and Production of CAR-T Therapy","volume":"15","author":"Zheng","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.isci.2026.115213_bib16","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13045-024-01639-1","article-title":"Advances in CAR-T cell therapy for hematologic and solid malignancies: latest updates from 2024 ESMO Congress","volume":"17","author":"Huang","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.isci.2026.115213_bib17","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.115213_bib18","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T cell therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.isci.2026.115213_bib19","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41408-024-01193-6","article-title":"Impact of T cell characteristics on CAR-T cell therapy in hematological malignancies","volume":"14","author":"Tao","year":"2024","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.isci.2026.115213_bib20","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s40164-024-00536-0","article-title":"CAR-T cell combination therapies in hematologic malignancies","volume":"13","author":"Zhou","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.isci.2026.115213_bib21","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1182\/bloodadvances.2023012255","article-title":"CAR T-cell therapy in mantle cell lymphoma with secondary CNS involvement: a multicenter experience","volume":"8","author":"Ahmed","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.isci.2026.115213_bib22","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1182\/bloodadvances.2023011896","article-title":"Clinical features of neurotoxicity after CD19 CAR T-cell therapy in mantle cell lymphoma","volume":"8","author":"Nie","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.isci.2026.115213_bib23","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000798","article-title":"Real-world Outcomes of Relapsed\/Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin-based Therapy","volume":"6","author":"Argnani","year":"2022","journal-title":"HemaSphere"},{"key":"10.1016\/j.isci.2026.115213_bib24","doi-asserted-by":"crossref","first-page":"5654","DOI":"10.1182\/bloodadvances.2025016315","article-title":"Treatment and outcomes of progression of disease post-CAR T-cell therapy in mantle cell lymphoma: a multicenter analysis","volume":"9","author":"Epstein-Peterson","year":"2025","journal-title":"Blood Adv."},{"key":"10.1016\/j.isci.2026.115213_bib25","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1172\/JCI83092","article-title":"Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition","volume":"126","author":"Cherkassky","year":"2016","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.isci.2026.115213_bib26","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1007\/s00262-021-02941-4","article-title":"CD19 CAR-T cell treatment conferred sustained remission in B-ALL patients with minimal residual disease","volume":"70","author":"Lu","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.isci.2026.115213_bib27","doi-asserted-by":"crossref","first-page":"182","DOI":"10.4049\/jimmunol.166.1.182","article-title":"Redirecting mouse CTL against colon carcinoma: superior signaling efficacy of single-chain variable domain chimeras containing TCR-zeta vs Fc epsilon RI-gamma","volume":"166","author":"Haynes","year":"2001","journal-title":"J. Immunol."},{"key":"10.1016\/j.isci.2026.115213_bib28","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.115213_bib29","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1158\/1078-0432.CCR-21-4097","article-title":"Autologous Nanobody-Derived Fratricide-Resistant CD7-CAR T-cell Therapy for Patients with Relapsed and Refractory T-cell Acute Lymphoblastic Leukemia\/Lymphoma","volume":"28","author":"Zhang","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2026.115213_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14112667","article-title":"Systematic Review of Available CAR-T Cell Trials around the World","volume":"14","author":"Barros","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.isci.2026.115213_bib31","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nm.3838","article-title":"4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2026.115213_bib32","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.22.00642","article-title":"Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed\/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial","volume":"41","author":"Laetsch","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.isci.2026.115213_bib33","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1200\/JCO.21.02370","article-title":"Three-Year Follow-Up of KTE-X19 in Patients With Relapsed\/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study","volume":"41","author":"Wang","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.isci.2026.115213_bib34","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s40164-025-00610-1","article-title":"Matching-adjusted indirect comparison of efficacy and safety of lisocabtagene maraleucel and mosunetuzumab for the treatment of third-line or later relapsed or refractory follicular lymphoma","volume":"14","author":"Nastoupil","year":"2025","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.isci.2026.115213_bib35","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-013904","article-title":"Third-generation CD28\/4-1BB chimeric antigen receptor T cells for chemotherapy relapsed or refractory acute lymphoblastic leukaemia: a non-randomised, open-label phase I trial protocol","volume":"6","author":"Tang","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.isci.2026.115213_bib36","doi-asserted-by":"crossref","first-page":"6185","DOI":"10.1158\/1078-0432.CCR-18-0426","article-title":"A Phase I\/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia","volume":"24","author":"Enblad","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2026.115213_bib37","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1182\/blood-2011-10-387969","article-title":"CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results","volume":"119","author":"Till","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.isci.2026.115213_bib38","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.96976","article-title":"Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation","volume":"3","author":"Guedan","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.isci.2026.115213_bib39","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1182\/blood.2023020854","article-title":"Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001","volume":"143","author":"Abramson","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.isci.2026.115213_bib40","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1200\/JCO.19.03279","article-title":"CD4\/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial","volume":"38","author":"Shah","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.isci.2026.115213_bib41","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2312374120","article-title":"Dual-inhibitory domain iCARs improve the efficiency of the AND-NOT gate CAR T strategy","volume":"120","author":"Bangayan","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2026.115213_bib42","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1016\/j.ymthe.2025.04.006","article-title":"High-dimensional temporal mapping of CAR T cells reveals phenotypic and functional remodeling during manufacturing","volume":"33","author":"Cadinanos-Garai","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.isci.2026.115213_bib43","article-title":"Cost-effective strategies for CAR-T cell therapy manufacturing","volume":"33","author":"Abdo","year":"2025","journal-title":"Mol. Ther. Oncol."},{"key":"10.1016\/j.isci.2026.115213_bib44","doi-asserted-by":"crossref","first-page":"e833","DOI":"10.1016\/S2352-3026(22)00245-9","article-title":"UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial","volume":"9","author":"Benjamin","year":"2022","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.isci.2026.115213_bib45","doi-asserted-by":"crossref","first-page":"5774","DOI":"10.1182\/bloodadvances.2022007317","article-title":"Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia","volume":"6","author":"Gill","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.isci.2026.115213_bib46","doi-asserted-by":"crossref","first-page":"4231","DOI":"10.7150\/ijbs.110406","article-title":"Enhancing CAR-T Cell Metabolic Fitness and Memory Phenotype for Improved Efficacy against Hepatocellular Carcinoma","volume":"21","author":"You","year":"2025","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.isci.2026.115213_bib47","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/s41586-024-07762-w","article-title":"Single-cell CAR T atlas reveals type 2 function in 8-year leukaemia remission","volume":"634","author":"Bai","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.isci.2026.115213_bib48","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s41467-019-13880-1","article-title":"Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy","volume":"11","author":"Sheih","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2026.115213_bib49","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1038\/s41591-020-1061-7","article-title":"Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas","volume":"26","author":"Deng","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2026.115213_bib50","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002328","article-title":"Single-cell multiomics dissection of basal and antigen-specific activation states of CD19-targeted CAR T cells","volume":"9","author":"Bai","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.isci.2026.115213_bib51","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1158\/2159-8290.CD-20-1677","article-title":"Integrative Bulk and Single-Cell Profiling of Premanufacture T-cell Populations Reveals Factors Mediating Long-Term Persistence of CAR T-cell Therapy","volume":"11","author":"Chen","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.isci.2026.115213_bib52","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1038\/s43018-024-00768-3","article-title":"Identification of a clinically efficacious CAR T cell subset in diffuse large B cell lymphoma by dynamic multidimensional single-cell profiling","volume":"5","author":"Rezvan","year":"2024","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.isci.2026.115213_bib53","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.830773","article-title":"Monitoring of Circulating CAR T Cells: Validation of a Flow Cytometric Assay, Cellular Kinetics, and Phenotype Analysis Following Tisagenlecleucel","volume":"13","author":"Peinelt","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2026.115213_bib54","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1158\/2643-3230.BCD-23-0112","article-title":"Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)","volume":"5","author":"Filosto","year":"2024","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.isci.2026.115213_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117252","article-title":"Antigen escape in CAR-T cell therapy: Mechanisms and overcoming strategies","volume":"178","author":"Lin","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.isci.2026.115213_bib56","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1172\/JCI87366","article-title":"Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies","volume":"126","author":"Ruella","year":"2016","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.isci.2026.115213_bib57","doi-asserted-by":"crossref","first-page":"958","DOI":"10.3324\/haematol.2020.266841","article-title":"BCMA loss in the epoch of novel immunotherapy for multiple myeloma: from biology to clinical practice","volume":"108","author":"Zhou","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.isci.2026.115213_bib58","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.1034257","article-title":"Mechanisms of CAR T cell exhaustion and current counteraction strategies","volume":"10","author":"Zhu","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.isci.2026.115213_bib59","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.imlet.2022.06.004","article-title":"The transcription factor TOX is involved in the regulation of T-cell exhaustion in neuroblastoma","volume":"248","author":"Pei","year":"2022","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.isci.2026.115213_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2021.101485","article-title":"Metabolic regulation of T cells in the tumor microenvironment by nutrient availability and diet","volume":"52","author":"Zhao","year":"2021","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.isci.2026.115213_bib61","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-47235-z","article-title":"Circulating levels of PD-L1 and Galectin-9 are associated with patient survival in surgically treated Hepatocellular Carcinoma independent of their intra-tumoral expression levels","volume":"9","author":"Sideras","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.isci.2026.115213_bib62","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1432799","article-title":"ReCARving the future: bridging CAR T-cell therapy gaps with synthetic biology, engineering, and economic insights","volume":"15","author":"Ali","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2026.115213_bib63","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/j.ymthe.2018.05.003","article-title":"Dominant-Negative TGF-beta Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication","volume":"26","author":"Kloss","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.isci.2026.115213_bib64","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.115213_bib65","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.115213_bib66","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.isci.2026.115213_bib67","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.isci.2026.115213_bib68","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.isci.2026.115213_bib69","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.annonc.2022.05.521","article-title":"Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomas","volume":"33","author":"Ghilardi","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.isci.2026.115213_bib70","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.isci.2026.115213_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.115973","article-title":"CAR-T cells containing CD28 versus 4-1BB co-stimulatory domains show distinct metabolic profiles in patients","volume":"44","author":"Cook","year":"2025","journal-title":"Cell Rep."},{"key":"10.1016\/j.isci.2026.115213_bib72","doi-asserted-by":"crossref","DOI":"10.1002\/hon.70125","article-title":"A SWOT-Consensus for CAR-T in Follicular Lymphoma: Fine Tuning of Patient Journey and Selection","volume":"43","author":"Marchetti","year":"2025","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.isci.2026.115213_bib73","first-page":"77.e7","article-title":"Real-World Outcomes with Chimeric Antigen Receptor T Cell Therapies in Large B Cell Lymphoma: A Systematic Review and Meta-Analysis","volume":"30","author":"Jacobson","year":"2024","journal-title":"Transplant. Cell. Ther."},{"key":"10.1016\/j.isci.2026.115213_bib74","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20230903","article-title":"CAR-T cell manufacturing: Major process parameters and next-generation strategies","volume":"221","author":"Ayala Ceja","year":"2024","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.isci.2026.115213_bib75","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.isci.2026.115213_bib76","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.isci.2026.115213_bib77","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1182\/blood.2025029368","article-title":"A burden too high for CAR T cells in CLL","volume":"146","author":"Kater","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.isci.2026.115213_bib78","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1182\/blood.2021011895","article-title":"Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed\/refractory CLL or SLL","volume":"139","author":"Siddiqi","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.isci.2026.115213_bib79","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.isci.2026.115213_bib80","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000186","article-title":"CAR T Cell Toxicity: Current Management and Future Directions","volume":"3","author":"Y\u00e1\u00f1ez","year":"2019","journal-title":"HemaSphere"},{"key":"10.1016\/j.isci.2026.115213_bib81","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.577027","article-title":"Cytokines in CAR T Cell-Associated Neurotoxicity","volume":"11","author":"Gust","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2026.115213_bib82","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jaci.2020.07.025","article-title":"Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies","volume":"146","author":"Freyer","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.isci.2026.115213_bib83","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1080\/1744666X.2019.1629904","article-title":"Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome","volume":"15","author":"Kotch","year":"2019","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1016\/j.isci.2026.115213_bib84","doi-asserted-by":"crossref","first-page":"e459","DOI":"10.1016\/S2352-3026(24)00077-2","article-title":"Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to management","volume":"11","author":"Rejeski","year":"2024","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.isci.2026.115213_bib85","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s40164-024-00573-9","article-title":"New insights into CAR T-cell hematological toxicities: manifestations, mechanisms, and effective management strategies","volume":"13","author":"Yang","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.isci.2026.115213_bib86","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/j.jacc.2019.10.038","article-title":"Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T)","volume":"74","author":"Alvi","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.isci.2026.115213_bib87","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1182\/blood.2021011898","article-title":"Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells","volume":"138","author":"Lichtenstein","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.isci.2026.115213_bib88","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41467-024-44873-4","article-title":"Bispecific BCMA\/CD24 CAR-T cells control multiple myeloma growth","volume":"15","author":"Sun","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2026.115213_bib89","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17020282","article-title":"Comprehensive Review of Early and Late Toxicities in CAR T-Cell Therapy and Bispecific Antibody Treatments for Hematologic Malignancies","volume":"17","author":"Bangolo","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.isci.2026.115213_bib90","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1182\/hematology.2023000472","article-title":"Recognizing, defining, and managing CAR-T hematologic toxicities","volume":"2023","author":"Rejeski","year":"2023","journal-title":"Hematology. Am. Soc. Hematol. Educ. Program"},{"key":"10.1016\/j.isci.2026.115213_bib91","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2025.1553966","article-title":"Management strategies for CAR-T cell therapy-related toxicities: results from a survey in Greece","volume":"12","author":"Gavriilaki","year":"2025","journal-title":"Front. Med."},{"key":"10.1016\/j.isci.2026.115213_bib92","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.isci.2026.115213_bib93","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.isci.2026.115213_bib94","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1200\/JCO-25-00760","article-title":"Long-Term (>\/=5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed\/Refractory Multiple Myeloma","volume":"43","author":"Jagannath","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.isci.2026.115213_bib95","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13045-025-01737-8","article-title":"Recent advances in universal chimeric antigen receptor T cell therapy","volume":"18","author":"Jiang","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.isci.2026.115213_bib96","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13045-025-01745-8","article-title":"Genome-edited allogeneic CAR-T cells: the next generation of cancer immunotherapies","volume":"18","author":"Su","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.isci.2026.115213_bib97","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jtct.2025.09.044","article-title":"Under the Hood: Evidence-Based Review of Allogeneic Chimeric Antigen Receptor T Cells for Hematologic Malignancies","volume":"32","author":"Cheema","year":"2026","journal-title":"Transplant. Cell. Ther."},{"key":"10.1016\/j.isci.2026.115213_bib98","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1557157","article-title":"Allogeneic CART progress: platforms, current progress and limitations","volume":"16","author":"Shokati","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2026.115213_bib99","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1182\/blood-2015-11-679134","article-title":"Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia","volume":"127","author":"Fraietta","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.isci.2026.115213_bib100","doi-asserted-by":"crossref","first-page":"5249","DOI":"10.1182\/bloodadvances.2025015881","article-title":"Real-world data for tisagenlecleucel in patients with R\/R B-ALL: subgroup analyses from the CIBMTR registry","volume":"9","author":"John","year":"2025","journal-title":"Blood Adv."},{"key":"10.1016\/j.isci.2026.115213_bib101","doi-asserted-by":"crossref","first-page":"351.e1","DOI":"10.1016\/j.jtct.2025.02.016","article-title":"Tisagenlecleucel in Practice: Real-World Lessons in Pediatric and Young Adult B-ALL","volume":"31","author":"McNerney","year":"2025","journal-title":"Transplant. Cell. Ther."},{"key":"10.1016\/j.isci.2026.115213_bib102","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101250","article-title":"CAR-T cell manufacturing landscape-Lessons from the past decade and considerations for early clinical development","volume":"32","author":"Dias","year":"2024","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.isci.2026.115213_bib103","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.832645","article-title":"Armored BCMA CAR T Cells Eliminate Multiple Myeloma and Are Resistant to the Suppressive Effects of TGF-beta","volume":"13","author":"Alabanza","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2026.115213_bib104","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/s41417-024-00750-2","article-title":"CAR T therapies in multiple myeloma: unleashing the future","volume":"31","author":"Sheykhhasan","year":"2024","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.isci.2026.115213_bib105","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/s41591-019-0549-5","article-title":"Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR","volume":"25","author":"Ghorashian","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2026.115213_bib106","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood-2010-12-326736","article-title":"Human T cells expressing affinity-matured TCR display accelerated responses but fail to recognize low density of MHC-peptide antigen","volume":"118","author":"Thomas","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.isci.2026.115213_bib107","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1182\/bloodadvances.2024015157","article-title":"Allogeneic off-the-shelf CAR T-cell therapy for relapsed or refractory B-cell malignancies","volume":"9","author":"Shahid","year":"2025","journal-title":"Blood Adv."},{"key":"10.1016\/j.isci.2026.115213_bib108","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41422-024-00936-1","article-title":"CAR-Toner: an AI-driven approach for CAR tonic signaling prediction and optimization","volume":"34","author":"Qiu","year":"2024","journal-title":"Cell Res."},{"key":"10.1016\/j.isci.2026.115213_bib109","doi-asserted-by":"crossref","DOI":"10.3389\/fmmed.2023.1250508","article-title":"Elaborating the potential of Artificial Intelligence in automated CAR-T cell manufacturing","volume":"3","author":"B\u00e4ckel","year":"2023","journal-title":"Front. Mol. Med."},{"key":"10.1016\/j.isci.2026.115213_bib110","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.isci.2026.115213_bib111","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1002\/cac2.12474","article-title":"Novel CD123xCD33 bicistronic chimeric antigen receptor (CAR)-T therapy has potential to reduce escape from single-target CAR-T with no more hematotoxicity","volume":"43","author":"Wang","year":"2023","journal-title":"Cancer Commun."},{"key":"10.1016\/j.isci.2026.115213_bib112","article-title":"Point-of-care manufacturing of anti-CD19 CAR-T cells using a closed production platform: Experiences of an academic in Thailand","volume":"32","author":"Luanpitpong","year":"2024","journal-title":"Mol. Ther. Oncol."},{"key":"10.1016\/j.isci.2026.115213_bib113","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1158\/1078-0432.CCR-24-1798","article-title":"Second Primary Malignancies after CAR T-Cell Therapy: A Systematic Review and Meta-analysis of 5,517 Lymphoma and Myeloma Patients","volume":"30","author":"Tix","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2026.115213_bib114","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1158\/2643-3230.BCD-23-0272","article-title":"The Fate(s) of CAR T-Cell Therapy: Navigating the Risks of CAR+ T-Cell Malignancy","volume":"5","author":"Abou-El-Enein","year":"2024","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.isci.2026.115213_bib115","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41591-023-02767-w","article-title":"Unanswered questions following reports of secondary malignancies after CAR-T cell therapy","volume":"30","author":"Levine","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2026.115213_bib116","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines13030758","article-title":"Scientific Advancements in Gene Therapies: Opportunities for Global Regulatory Convergence","volume":"13","author":"Olaghere","year":"2025","journal-title":"Biomedicines"}],"container-title":["iScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004226005882?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004226005882?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:01:57Z","timestamp":1790694117000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589004226005882"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":116,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2589004226005882"],"URL":"https:\/\/doi.org\/10.1016\/j.isci.2026.115213","relation":{},"ISSN":["2589-0042"],"issn-type":[{"value":"2589-0042","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CAR T-cells in hematologic malignancies: Advances, challenges, and future directions","name":"articletitle","label":"Article Title"},{"value":"iScience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.isci.2026.115213","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"115213"}}